REMdesivir-HU Clinical Study and Severe Covid-19 Patients

Inclusion Criteria: * Males or females aged 12yrs and older with body weight at least 40kg * Hospitalized with COVID-19 confirmed by PCR and/or COVID-19 typical symptoms with pneumonia: ▪ In case of no confirmed PCR test result available at screening, typical symptoms can also apply * requiring supplemental oxygen at screening ▪ at the discretion of the investigator, any form of O2 support can apply * Do not have access to Veklury treatment ▪ Patient may be under other treatment against COVID-19 (except for chloroquine/hydroxychloroquine) * Willing and able to provide valid written informed consent prior to performing study procedures (for those \<18yrs of age, parental consent and patient assent is required). For an unconscious or comatose patient written informed consent given by next of kin or a legal representative is also accepted. If none of the above consents are available the investigator can enroll the patient as described in 21 CFR 50.24 (involving emergency research). Exclusion Criteria: Known liver disease, hepatic impairment and/or Alanine Transaminase (ALT) or Aspartate Transaminase (AST) ≥ 5 times the upper limit of normal * Known severe renal disease (including patients receiving hemodialysis or hemofiltration) and/or estimated glomerular filtration rate (eGFR) \< 30 ml/min. * Pregnancy or breast feeding at the discretion of the investigator * Anticipated discharge from the hospital or transfer to another hospital which is not a study site within 120 hours * Know allergy to any anti-viral medication * Hypersensitivity to the active substance(s) or to any of the excipients * Current (or 48 hours prior) treatment with chloroquine/hydroxychloroquine Other investigationsl treatment up to 2x the "emptying" time of treatment, or if this is not known for 60 days, except in the case of a favipiravir study. In case of the clinical trial of favipiravir the petinents can be enrolled in the study if afterthe end of study / early termination visit. * Any medical condition that the examining physician deems unsuitable for the patient to participate in the study.